Clinical Trials Logo

Clinical Trial Summary

Cefiderocol is a new antibiotic from the siderophore cephalosporin family for which there are few real-life data on its use in the treatment of infections with multidrug-resistant Gram-negative bacilli. The circulation of bacterial strains multi-resistant to antibiotics is important at the Strasbourg University Hospital, so the investigators wish to report their local experience of the 1st uses of Cefiderocol in the treatment of infections with multi-resistant Gram-negative bacilli to antibiotics in order to better clarify the use of this antibiotic (therapeutic indication, method of administration)


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT05544682
Study type Observational
Source University Hospital, Strasbourg, France
Contact Yvon RUCH, MD
Phone 33 3 69 55 05 45
Email yvon.ruch@chru-strasbourg.fr
Status Recruiting
Phase
Start date September 1, 2022
Completion date December 2023